A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid Tumors

Eric Van Cutsem(Universitair Ziekenhuis Leuven), David Cunningham(Royal Marsden NHS Foundation Trust), Veena Shankaran(University of Washington), Salvatore Siena(University of Milan), Hui Yang(Amgen (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Hyun Cheol Chung(Yonsei University), Yoon‐Koo Kang(Ulsan College), Ning Go(Amgen (United States)), Marco Schupp(Amgen (Switzerland))
Clinical Cancer Research
October 26, 2018
10.1158/1078-0432.ccr-18-1337
Cited by 73

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k